Glue-based KRAS inhibitors make their debut cancer trial mark

Glue-based KRAS inhibitors make their debut cancer trial mark

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Drug discovery 2023-12, Vol.22 (12), p.942-942
1. Verfasser: Mullard, Asher
Format: Artikel
Sprache:eng
Schlagworte:
Biomedicine
Biotechnology
Cancer Research
Colorectal Neoplasms
Humans
Medicinal Chemistry
Molecular Medicine
Mutation
News In Brief
Pharmacology/Toxicology
Proto-Oncogene Proteins p21(ras) - genetics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 942
container_issue 12
container_start_page 942
container_title Nature reviews. Drug discovery
container_volume 22
creator Mullard, Asher
description
doi_str_mv 10.1038/d41573-023-00169-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2881244535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2881244535</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-134cb04b1869b6af4b8de6821f7d25b1f89b12a31b4f18a13065ff0cefcb5c713</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EolB4AQYUiYUl4ONL7AwMCHETSEhcZst2bJo2TYqdDLw9Li1FYmCwjqXznd8-H0JHgM8AU3leMeCC5pikg6Eoc7mF9oAJloOQbHtzF8UI7cc4XUIgyC4aUSEFoYTvoYvbZnC50dFV2cPz5UtWt5Pa1H0XYjbXM5f1E1eHrHJm6DOrW-tC1odaN6kbZgdox-smusN1HaO3m-vXq7v88en2_uryMbdU8D4HyqzBzIAsSlNoz4ysXCEJeFERbsDL0gDRFAzzIDVQXHDvsXXeGm4F0DE6XeUuQvcxuNireR2taxrdum6IikgJhDFOeUJP_qDTbght-l2iSsZLgvmSIivKhi7G4LxahDpt9KkAq6VctZKrklz1LVfJNHS8jh7M3FWbkR-bCaArIKZW--7C79v_xH4BG_WCkg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2894592055</pqid></control><display><type>article</type><title>Glue-based KRAS inhibitors make their debut cancer trial mark</title><source>MEDLINE</source><source>Nature</source><source>Springer Nature - Complete Springer Journals</source><creator>Mullard, Asher</creator><creatorcontrib>Mullard, Asher</creatorcontrib><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/d41573-023-00169-8</identifier><identifier>PMID: 37872325</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Biomedicine ; Biotechnology ; Cancer Research ; Colorectal Neoplasms ; Humans ; Medicinal Chemistry ; Molecular Medicine ; Mutation ; News In Brief ; Pharmacology/Toxicology ; Proto-Oncogene Proteins p21(ras) - genetics</subject><ispartof>Nature reviews. Drug discovery, 2023-12, Vol.22 (12), p.942-942</ispartof><rights>Springer Nature Limited 2023</rights><rights>Springer Nature Limited 2023.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-134cb04b1869b6af4b8de6821f7d25b1f89b12a31b4f18a13065ff0cefcb5c713</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/d41573-023-00169-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/d41573-023-00169-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37872325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mullard, Asher</creatorcontrib><title>Glue-based KRAS inhibitors make their debut cancer trial mark</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><addtitle>Nat Rev Drug Discov</addtitle><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Cancer Research</subject><subject>Colorectal Neoplasms</subject><subject>Humans</subject><subject>Medicinal Chemistry</subject><subject>Molecular Medicine</subject><subject>Mutation</subject><subject>News In Brief</subject><subject>Pharmacology/Toxicology</subject><subject>Proto-Oncogene Proteins p21(ras) - genetics</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kLtOwzAUhi0EolB4AQYUiYUl4ONL7AwMCHETSEhcZst2bJo2TYqdDLw9Li1FYmCwjqXznd8-H0JHgM8AU3leMeCC5pikg6Eoc7mF9oAJloOQbHtzF8UI7cc4XUIgyC4aUSEFoYTvoYvbZnC50dFV2cPz5UtWt5Pa1H0XYjbXM5f1E1eHrHJm6DOrW-tC1odaN6kbZgdox-smusN1HaO3m-vXq7v88en2_uryMbdU8D4HyqzBzIAsSlNoz4ysXCEJeFERbsDL0gDRFAzzIDVQXHDvsXXeGm4F0DE6XeUuQvcxuNireR2taxrdum6IikgJhDFOeUJP_qDTbght-l2iSsZLgvmSIivKhi7G4LxahDpt9KkAq6VctZKrklz1LVfJNHS8jh7M3FWbkR-bCaArIKZW--7C79v_xH4BG_WCkg</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Mullard, Asher</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20231201</creationdate><title>Glue-based KRAS inhibitors make their debut cancer trial mark</title><author>Mullard, Asher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-134cb04b1869b6af4b8de6821f7d25b1f89b12a31b4f18a13065ff0cefcb5c713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Cancer Research</topic><topic>Colorectal Neoplasms</topic><topic>Humans</topic><topic>Medicinal Chemistry</topic><topic>Molecular Medicine</topic><topic>Mutation</topic><topic>News In Brief</topic><topic>Pharmacology/Toxicology</topic><topic>Proto-Oncogene Proteins p21(ras) - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mullard, Asher</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mullard, Asher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glue-based KRAS inhibitors make their debut cancer trial mark</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><addtitle>Nat Rev Drug Discov</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>22</volume><issue>12</issue><spage>942</spage><epage>942</epage><pages>942-942</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37872325</pmid><doi>10.1038/d41573-023-00169-8</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1474-1776
ispartof Nature reviews. Drug discovery, 2023-12, Vol.22 (12), p.942-942
issn 1474-1776
1474-1784
language eng
recordid cdi_proquest_miscellaneous_2881244535
source MEDLINE; Nature; Springer Nature - Complete Springer Journals
subjects Biomedicine
Biotechnology
Cancer Research
Colorectal Neoplasms
Humans
Medicinal Chemistry
Molecular Medicine
Mutation
News In Brief
Pharmacology/Toxicology
Proto-Oncogene Proteins p21(ras) - genetics
title Glue-based KRAS inhibitors make their debut cancer trial mark
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A00%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glue-based%20KRAS%20inhibitors%20make%20their%20debut%20cancer%20trial%20mark&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.au=Mullard,%20Asher&rft.date=2023-12-01&rft.volume=22&rft.issue=12&rft.spage=942&rft.epage=942&rft.pages=942-942&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/d41573-023-00169-8&rft_dat=%3Cproquest_cross%3E2881244535%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2894592055&rft_id=info:pmid/37872325&rfr_iscdi=true